Despite these growth factors, there are concerns about the potential impact of a shift in the mix toward multilisted options and XSP on revenue per contract (RPC (NYSE:RES)). RBC Capital also noted ...
MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback